1. Introduction

Residual biological materials are human or other biological substances that remain after a medical procedure, diagnostic test, research activity, manufacturing process, or other biological operation. They may include blood samples, discarded tissue, excised organs, surgical waste, extracted DNA, stored embryos, reproductive materials, and biological specimens left over after clinical testing.

Their legal treatment raises important questions of ownership, consent, privacy, scientific research, commercial exploitation, disposal, and liability. A sample initially collected for medical treatment may later become valuable for genetic research, pharmaceutical development, or biotechnology commercialization.

The central legal question is: Who has the legal authority to retain, use, transfer, commercialize, or destroy residual biological material, and what rights survive after its original purpose has ended?

There is no single universal rule. The answer depends on the nature of the material, the purpose for which it was collected, applicable legislation, consent terms, and the jurisdiction concerned.

2. Meaning and classification

Residual biological materials can be divided into several categories.

An important distinction is that physical specimens, genetic information derived from them, and inventions developed using them may be governed by different legal rules. Ownership or lawful possession of a sample does not automatically confer unrestricted rights over the information it contains.

3. Legal framework in India

In India, the treatment of residual biological materials is governed by a combination of ethical guidelines, medical-consent principles, biosafety requirements, privacy rules, and subject-specific legislation.

A. ICMR National Ethical Guidelines

The Indian Council of Medical Research (ICMR) National Ethical Guidelines for Biomedical and Health Research Involving Human Participants address biological specimens, biobanking, and datasets. They expressly cover leftover clinical samples, biopsy materials, surgical specimens, cell lines, reproductive materials, and biological waste.

sts.icmr.org.in+1

The principal considerations include:

Informed consent: Consent should appropriately cover collection, storage, future research, and any proposed commercial use.

Ethics committee review: Research involving human biological materials and associated data must undergo the applicable ethical review.

Confidentiality: Identifiable specimens and genetic information require appropriate safeguards.

Withdrawal: Participants may request withdrawal or destruction of samples in appropriate circumstances, subject to limitations where specimens have been irreversibly anonymised or incorporated into completed research.

Commercial use: The consent process should address potential commercialisation and whether donors, their families, or communities may receive benefits.

The ICMR framework is a central ethical reference for Indian biomedical research, but its legal effect must be distinguished from that of a statute or binding regulation.

B. Biomedical Waste Management Rules, 2016

The Biomedical Waste Management Rules, 2016, issued under India's environmental legislation, regulate the handling, segregation, treatment, and disposal of covered biomedical waste.

Where residual material has become biomedical waste, healthcare facilities must comply with applicable segregation, storage, transport, treatment, and disposal requirements. Human anatomical waste, contaminated materials, and laboratory waste may be subject to different handling requirements.

Legal principle: Residual biological material cannot be treated as ordinary refuse merely because its original clinical purpose has ended. Its classification and potential hazards determine the applicable disposal duties.

C. Medical consent and professional duties

Indian medical law recognises the importance of valid informed consent. Consent to remove tissue for diagnosis or treatment should not automatically be assumed to authorise every later research, genetic-testing, or commercial use.

The scope of the original consent, the disclosures made to the patient, and the nature of the subsequent use are important in determining whether additional consent or ethics approval is required.

D. Privacy and genetic information

Residual biological specimens may contain highly sensitive personal information, including genetic predispositions, familial relationships, and disease risks.

The Supreme Court's constitutional privacy jurisprudence is relevant to the collection, retention, disclosure, and secondary use of such information. Depending on the circumstances, applicable data-protection legislation and other confidentiality requirements may also apply.

E. Special rules for reproductive materials

Stored gametes and embryos cannot simply be treated as ordinary laboratory leftovers. Their storage, use, transfer, and disposal may engage the Assisted Reproductive Technology (Regulation) Act, 2021, its rules, consent requirements, and other applicable legal safeguards.

The legal position is therefore materially different for an unused blood sample, a surgically removed tumour, and an embryo stored for reproductive purposes.

4. Important case laws

The following decisions illustrate the major legal principles. Most of the leading cases directly concerning residual human tissue originate in the United States; they are persuasive comparative authorities, not binding precedents in India.

Case 1: Moore v. Regents of the University of California (1990)

Supreme Court of California · 51 Cal. 3d 120 · 793 P.2d 479

Facts: John Moore's cells were removed during medical treatment. His physician subsequently used the cells in research that led to a commercially valuable cell line. Moore alleged that the physician had failed to disclose relevant research and financial interests.

Legal issue: Did Moore retain a property interest sufficient to bring a conversion claim over the removed cells, and did the physician have a duty to disclose the research interests?

Decision: The court rejected Moore's conversion claim concerning the excised cells but allowed claims based on breach of fiduciary duty and lack of informed consent to proceed.

California Supreme Court Resources+1

Legal principle:

Removal of biological material does not necessarily leave the donor with an enforceable property claim over every subsequent research product.

Physicians must disclose material research or financial interests that may affect medical judgment.

The absence of a conventional property right does not eliminate potential liability for deficient consent.

Relevance to India: A hospital or researcher should not assume that obtaining tissue for a clinical procedure gives unrestricted authority to exploit it commercially. The consent process and the duty to disclose material interests remain important.

Case 2: Greenberg v. Miami Children's Hospital Research Institute (2003)

United States District Court, Southern District of Florida · 264 F. Supp. 2d 1064

Facts: Families affected by Canavan disease contributed tissue, blood samples, and research assistance to help identify the genetic cause of the disease. The resulting research produced a patented gene-related invention and diagnostic tests.

Legal issue: Could the donors challenge the researchers' commercialisation of discoveries made using their contributions?

Decision: The court dismissed several claims, including conversion and certain consent-related claims, but allowed an unjust-enrichment claim to proceed on the facts alleged concerning the donors' substantial contributions to an ongoing research collaboration.

pubmed.ncbi.nlm.nih.gov+1

Legal principle:

Donating a specimen does not automatically give a donor ownership of every later discovery.

The terms and circumstances of a research collaboration can matter independently of ownership.

Commercial exploitation may create distinct legal questions where there are representations, promises, or substantial contributions beyond merely supplying tissue.

Relevance to India: Consent forms and research agreements should clearly address intellectual property, commercial development, benefit-sharing arrangements, and any representations made to donors.

Case 3: Washington University v. Catalona (2007)

United States Court of Appeals for the Eighth Circuit · 490 F.3d 667

Facts: A dispute arose over biological specimens donated by research participants for genetic cancer research at Washington University. A former researcher sought to facilitate transfer of the samples to another institution.

Legal issue: Did the donors retain ownership rights that allowed them to direct the transfer of the specimens?

Decision: The court upheld the finding that the university owned the samples under the donation arrangements and applicable Missouri law. The outcome depended on the terms and circumstances of the donations.

law.justia.com+1

Legal principle:

The recipient institution's legal rights depend on the applicable law and the terms of the transfer.

Donor consent and institutional custody do not invariably amount to continuing donor ownership.

Transfer, withdrawal, and destruction rights must be analysed separately.

Relevance to India: Research institutions should define the rights and responsibilities of donors, custodians, researchers, and collaborating institutions in consent documents and material-transfer agreements.

Case 4: Samira Kohli v. Dr. Prabha Manchanda (2008)

Supreme Court of India · (2008) 2 SCC 1

Facts: A patient underwent a gynaecological procedure. The dispute concerned the scope of consent for treatment and an additional procedure performed during surgery.

Legal issue: What constitutes valid informed consent for medical intervention?

Decision: The Supreme Court explained the requirements of valid consent and held that consent for one procedure does not ordinarily authorise a materially different procedure, subject to recognised exceptions such as a genuine emergency.

Legal principle: Consent must be real, voluntary, and sufficiently informed for the intervention undertaken.

Relevance to residual biological materials: Although the case did not concern biobanking or leftover tissue, its reasoning is relevant when assessing whether consent for clinical treatment extends to secondary research or another materially different purpose. It should not be interpreted as establishing a universal requirement of separate consent for every use of a specimen; the applicable research rules and original consent terms must also be considered.

Case 5: Justice K.S. Puttaswamy (Retd.) v. Union of India (2017)

Supreme Court of India · (2017) 10 SCC 1

Facts: The litigation concerned the constitutional status of privacy in India.

Legal issue: Is privacy a constitutionally protected fundamental right?

Decision: A nine-judge bench unanimously recognised privacy as a fundamental right under Article 21 and the broader framework of Part III of the Constitution.

Legal principle: Privacy protects aspects of personal autonomy, dignity, and control over personal information, subject to constitutionally permissible restrictions.

Relevance to residual biological materials: The decision provides an important constitutional foundation for examining the privacy implications of retaining identifiable tissue, analysing genomes, disclosing genetic findings, or using biological specimens to infer sensitive information. It does not, by itself, determine who owns a specimen or establish a complete code for biological-material research.

5. Core legal issues

A. Consent and secondary use

The original purpose of collection is a critical starting point. A sample collected for diagnosis may later be proposed for population genetics research, AI model development, or commercial testing. The proposed use must be assessed against the consent obtained, applicable guidelines, ethics approvals, and legal restrictions.

B. Ownership and custody

Ownership is not a universal, settled rule across all biological materials. A patient may have recognised rights over the specimen or its use, while a hospital or biobank may lawfully possess and manage it. The legal position depends on applicable law, consent, donation terms, and the specimen's nature.

C. Privacy and confidentiality

Removing a patient's name may reduce identification risks but does not necessarily eliminate them. Genetic sequences can sometimes be linked to individuals or relatives. Appropriate access controls, data minimisation, confidentiality protections, and restrictions on disclosure are therefore important.

D. Commercialisation and benefit-sharing

A company may develop a diagnostic product, cell line, or therapeutic technology using residual material. Whether the donor has a right to compensation depends on applicable law, contractual commitments, representations, and the particular circumstances. Supplying a sample does not automatically entitle the donor to a share of all resulting profits.

E. Retention and destruction

Institutions should establish lawful retention periods, storage conditions, withdrawal procedures, and disposal protocols. They must also consider whether the specimen is subject to a legal hold, a clinical-record retention requirement, a research protocol, or a specific reproductive-material rule.

6. Liability for unlawful handling

Unlawful retention or use of residual biological materials may result in different forms of liability depending on the facts.

A breach of an ethical guideline does not automatically constitute a criminal offence. The relevant statute, regulatory requirement, contractual obligation, or recognised cause of action must be identified.

Potential remedies may include an injunction, cessation of unauthorised use, lawful destruction or return of specimens, compensation where legally available, regulatory sanctions, or other appropriate relief.

7. Practical example

Suppose a hospital collects a patient's blood to investigate a suspected genetic disorder. After the diagnosis is complete, a laboratory wishes to retain the remaining sample and use it to develop a commercially marketed genetic test.

The legal analysis should proceed as follows:

Identify the specimen: Is it a clinical remnant, a research specimen, or material already classified as biomedical waste?

Review consent: Does the consent cover storage, future research, genetic analysis, and commercial development?

Check ethical approval: Is the proposed research covered by an approved protocol, or is additional review required?

Protect privacy: Can the material be used in a less identifiable form, and what safeguards apply to associated genetic data?

Examine commercial terms: Were benefit-sharing arrangements or promises of non-commercial use made?

Determine withdrawal rights: Can the participant require discontinuation of use or destruction of the sample, and are any exceptions applicable?

Document disposal or retention: If further use is not authorised, follow the applicable retention, transfer, and disposal requirements.

The hospital cannot safely conclude that the sample is free for any use merely because the diagnostic procedure has ended.

8. Key legal principles

The law of residual biological materials can be summarised through six principles:

Purpose limitation: Material collected for one purpose is not automatically available for every other purpose.

Informed consent: Consent must be evaluated in light of the proposed activity and applicable legal requirements.

Conditional control: Possession, ownership, authority to use, and the right to withdraw are distinct legal questions.

Privacy protection: Biological specimens and the information derived from them can engage different privacy obligations.

Accountable commercialisation: Research agreements and consent processes should transparently address commercial development and promised benefits.

Safe disposition: Residual material must be retained, transferred, or disposed of in accordance with applicable legal and safety requirements.

9. Conclusion

The legal treatment of residual biological materials lies at the intersection of medical law, research ethics, property law, privacy, biotechnology regulation, and environmental health.

The decisions in Moore, Greenberg, and Washington University v. Catalona demonstrate that ownership of biological specimens, informed consent, institutional custody, and commercial rights must be analysed separately. In India, Samira Kohli and Puttaswamy supply important principles concerning informed consent and privacy, while ICMR guidance provides a central framework for biomedical research and biobanking.

The principal conclusion is that residual biological material is not automatically ownerless or freely usable once its original purpose ends. Its lawful treatment depends on the applicable legal framework, consent and transfer terms, the intended use, privacy safeguards, and any special rules governing the material.

Academic note: This is a general legal analysis, not a determination of the law applicable to every specimen. For a real dispute, the jurisdiction, specimen type, consent form, and proposed use should be examined together.